NYSE:MDT - Medtronic Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$87.97 +0.40 (+0.46 %)
(As of 05/21/2019 12:27 PM ET)
Previous Close$87.57
Today's Range$87.93 - $88.68
52-Week Range$81.66 - $100.15
Volume156,073 shs
Average Volume5.79 million shs
Market Capitalization$117.98 billion
P/E Ratio18.43
Dividend Yield2.28%
Beta0.78
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP58505510
Phone353-1438-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.95 billion
Cash Flow$6.7773 per share
Book Value$37.50 per share

Profitability

Net Income$3.10 billion

Miscellaneous

Employees86,000
Outstanding Shares1,341,151,000
Market Cap$117.98 billion
Next Earnings Date5/23/2019 (Confirmed)
OptionableOptionable

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic declared a quarterly dividend on Monday, March 11th. Investors of record on Friday, March 22nd will be paid a dividend of $0.50 per share on Friday, April 12th. This represents a $2.00 annualized dividend and a yield of 2.27%. The ex-dividend date of this dividend is Thursday, March 21st. View Medtronic's Dividend History.

How will Medtronic's stock buyback program work?

Medtronic announced that its board has initiated a share buyback program on Thursday, October 5th 2017, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 49% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its shares are undervalued.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) announced its quarterly earnings data on Tuesday, August, 21st. The medical technology company reported $1.17 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.11 by $0.06. The medical technology company had revenue of $7.38 billion for the quarter, compared to analyst estimates of $7.24 billion. Medtronic had a net margin of 16.10% and a return on equity of 13.85%. The business's revenue was down .1% on a year-over-year basis. During the same period last year, the business earned $1.12 earnings per share. View Medtronic's Earnings History.

When is Medtronic's next earnings date?

Medtronic is scheduled to release their next quarterly earnings announcement on Thursday, May 23rd 2019. View Earnings Estimates for Medtronic.

How can I listen to Medtronic's earnings call?

Medtronic will be holding an earnings conference call on Thursday, May 23rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What price target have analysts set for MDT?

23 brokers have issued 1 year price objectives for Medtronic's stock. Their forecasts range from $84.00 to $120.00. On average, they expect Medtronic's share price to reach $103.3182 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price. View Analyst Price Targets for Medtronic.

What is the consensus analysts' recommendation for Medtronic?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 8 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:
  • 1. According to Zacks Investment Research, "The declining CRHF segment raises concern for Medtronic. Escalating costs and expenses continue to weigh on Medtronic’s bottom line. On a positve note, in the past year, shares of Medtronic outperformed its industry. The company is successfully registering sustainable growth across major groups and regions, in addition to displaying successful achievement of synergy targets. The company is focusing on geographical diversification of its businesses. This apart, the company has been seeing certain favorable developments in its Diabetes business. The updated 2019 guidance with raised EPS view increases investors’ confidence on the stock. Meanwhile, we are optimistic about the recently-closed acquisition of Mazor Robotics which is expected to fortify Medtronic's position in spine surgery." (5/20/2019)
  • 2. Northland Securities analysts commented, "We highlight these results vis-a-vis Edwards’ PARTNER-3 Study which showed superiority at 1-year in the SAPIEN 3 arm. We note that there remain numerous unanswered questions in this cohort of low-risk patients. the trial This trial was a 1:1 randomized study using hierarchical endpoint analysis for non-inferiority first, and then on superiority." (3/18/2019)
  • 3. Barclays PLC analysts commented, "We now project $5.15 versus $5.12 consensus. Formal FY20 guidance will come in May but mgmt expressed comfort with the Street EPS estimate (per Refinitiv $5.44) which implies ~5.6% y/y growth off the revised mid- point for FY19. In Jan, mgmt said a higher tax rate could prompt EPS growth to be up to 250bp below its 8% long-range plan (LRP) CAGR target. Mgmt noted it is still working through its options for financial engineering. We think FY20 is likely a back- end loaded year given revenue cadence considerations (i.e. comps, new products launches) as well as FX impacts. We now est. $5.42 vs. $5.38 prior. Net/net, nothing materially changed our view. We think the valuation offers some upside and we rate MDT OW. That said, the upside case may take time to work out as execution confidence builds and many pipeline milestones are more 2020 events." (2/20/2019)

Has Medtronic been receiving favorable news coverage?

News stories about MDT stock have trended somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medtronic earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned news stories about the medical technology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days.

Who are some of Medtronic's key competitors?

What other stocks do shareholders of Medtronic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medtronic investors own include Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), General Electric (GE), AbbVie (ABBV), NVIDIA (NVDA), First Financial (THFF) and CVS Health (CVS).

Who are Medtronic's key executives?

Medtronic's management team includes the folowing people:
  • Mr. Omar S. Ishrak, Chairman & CEO (Age 63)
  • Ms. Karen L. Parkhill, Exec. VP, CFO & Principal Accounting Officer (Age 54)
  • Mr. Bradley E. Lerman, Sr. VP, Gen. Counsel & Company Sec. (Age 61)
  • Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 57)
  • Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 58)

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.96%), Wellington Management Group LLP (5.10%), Lazard Asset Management LLC (2.07%), Geode Capital Management LLC (1.31%), Northern Trust Corp (1.25%) and Wells Fargo & Company MN (1.02%). Company insiders that own Medtronic stock include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Geoffrey Martha, Hooman Hakami, James T Lenehan, Karen L Parkhill, Michael J Coyle, Omar Ishrak, Richard H Anderson and Richard Kuntz. View Institutional Ownership Trends for Medtronic.

Which major investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Morgan Stanley, FMR LLC, Caisse DE Depot ET Placement DU Quebec, GQG Partners LLC, Primecap Management Co. CA, Amundi Pioneer Asset Management Inc. and The Manufacturers Life Insurance Company . Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Geoffrey Martha, Hooman Hakami, Michael J Coyle and Richard Kuntz. View Insider Buying and Selling for Medtronic.

Which major investors are buying Medtronic stock?

MDT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Lazard Asset Management LLC, Nordea Investment Management AB, AQR Capital Management LLC, Hotchkis & Wiley Capital Management LLC, American Century Companies Inc., Boston Partners and Neuberger Berman Group LLC. Company insiders that have bought Medtronic stock in the last two years include Karen L Parkhill, Omar Ishrak and Richard H Anderson. View Insider Buying and Selling for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $88.07.

How big of a company is Medtronic?

Medtronic has a market capitalization of $118.12 billion and generates $29.95 billion in revenue each year. The medical technology company earns $3.10 billion in net income (profit) each year or $4.77 on an earnings per share basis. Medtronic employs 86,000 workers across the globe.

What is Medtronic's official website?

The official website for Medtronic is http://www.medtronic.com.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]


MarketBeat Community Rating for Medtronic (NYSE MDT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,189 (Vote Outperform)
Underperform Votes:  709 (Vote Underperform)
Total Votes:  1,898
MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/21/2019 by MarketBeat.com Staff

Featured Article: What is a Futures Contract?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel